← Back to Search

Other

NoNO-42 for Acute Ischemic Stroke Treatment

Phase 1
Waitlist Available
Research Sponsored by NoNO Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is testing the safety, tolerability and how the body absorbs a new drug, NoNO-42, in healthy adults. Participants will be monitored for 24 hours after taking the drug.

Eligible Conditions
  • First-In-Human Study for Acute Ischemic Stroke Treatment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of AEs, abnormal laboratory findings and abnormal vital signs
Secondary outcome measures
Pharmacokinetics of NoNO-42 following administration of a single ascending IV dose

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NoNO-42Experimental Treatment1 Intervention
A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
Group II: PlaceboPlacebo Group1 Intervention
A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NoNO-42
2022
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

NoNO Inc.Lead Sponsor
6 Previous Clinical Trials
3,272 Total Patients Enrolled
~33 spots leftby Jun 2025